ZappRx and Teva Respiratory Collaborate to Speed Delivery of Specialty Medication

Partnership provides physicians using the ZappRx prescribing platform
with a streamlined way to prescribe respiratory medication and provide
access to associated programs

BOSTON–(BUSINESS WIRE)–ZappRx®,
a healthcare technology company that streamlines the complex processes
associated with prescribing specialty medications, announced today that
it will work with Teva Respiratory, LLC, in support of their specialty
respiratory medication. The joint project will provide a more efficient
approach to prescribe, obtain, and administer therapy necessary for
patients to better manage their disease and symptoms.

“By partnering with industry leaders such as Teva Respiratory, ZappRx is
able to make life-changing medications more accessible to an underserved
patient population,” said Zoë Barry, CEO and Founder of ZappRx. “ZappRx
is committed to helping patients first and foremost, and we are
confident that working with Teva will help us to do exactly that.”

ZappRx’s cloud-based platform streamlines what is currently a
multi-step, manual prescribing process, often involving numerous
platforms for each of several treatments, into a single,
digitally-enabled format. This allows providers who treat severe asthma
to focus more on patient care.

To learn more about ZappRx and the work it is doing to improve care for
patients in need, visit them online at www.zapprx.com.

About ZappRx
ZappRx streamlines the complex process required
to order specialty medications, increasing efficiencies when collecting
and maintaining the myriad requisite information for ordering specialty
drugs — including pharmacy information, payer/prior authorization
requirements, and relevant clinical history. ZappRx then enables
providers, pharmacists, and payers to digitally interact with one
another to fill a prescription, reducing the need for faxes and phone
calls. The platform currently is live in Pulmonary (including Cystic
Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic
Pulmonary Fibrosis (IPF)), Severe Asthma, Cardiology (including
Hyperlipidemia and Congestive Heart Failure), and Gastroenterology
(including Crohn’s Disease and Ulcerative Colitis). As the company
grows, ZappRx plans to expand into other areas, including Rheumatology,
Neurology, and Oncology.

Connect with ZappRx on Twitter
and LinkedIn.

ZappRx and the “Z” logo are registered trademarks of ZappRx, Inc.

Contacts

Matter for ZappRx
Jessica Wolter
978-518-4536
[email protected]
www.matternow.com

error: Content is protected !!